In a bid to support regulatory review, the FDA expects to deploy artificial intelligence across all of its centers by the end of June, the agency announced Thursday.
The announcement comes as the FDA completes its pilot scientific review using a generative AI model. “I was blown away by the success of our first AI-assisted scientific review pilot,” Commissioner Marty Makary said in a statement on Thursday, though the agency did not provide specific…
Article Source
https://www.biospace.com/fda/amid-layoffs-delays-fda-turns-to-ai-for-speedy-reviews
